Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration[1][2].
Gypenoside LI (0-80 μM) inhibits A549 cells in a dose-dependent manner. Gypenoside LI induces G2/M and arrest apoptosis in A549 cells[1].Gypenoside LI increases intracellular ROS level. Gypenoside LI suppressed migration of A549 cells[1].Gypenoside LI could obviously suppress the expression of CDK1 protein rather thanCDK2 and CDK4 proteins[1].Gypenoside LI inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells[2].Gypenoside LI (75 and 29.71 μg/mL) can induce intrinsic apoptosis along with S phase arrest. Gypenoside LI inhibited the colony formation ability of melanoma through inhibition of the Wnt/β-catenin signaling pathway[2].Gypenoside LI induces PARP cleavage, increased the expression of cleaved caspase-9 and BID death agonist, and downregulates the expression of FLIP (long form) and BCl-2 in the A375 and SK-MEL-28 melanoma cells[2].
[1]. Shao-Fang Xing, et al. The inhibitory effect of gypenoside stereoisomers, gypenoside L and gypenoside LI, isolated from Gynostemma pentaphyllum on the growth of human lung cancer A549 cells. J Ethnopharmacol. 2018 Jun 12;219:161-172.
[2]. Ma-Li Zu, et al. Monomer gypenoside LI from Gynostemma pentaphyllum inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells. J Biochem Mol Toxicol. 2020 May;34(5):e22460.